Lacking of sufficient treatments

PharmNovo AB is a clinical-phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain.

Neuropathic pain affects up to ten percent of the population in Europe and the United States, and there is a lack of sufficient treatment.  Existing chronic pain drugs are only partly effective and only for some patients, and they are associated with significant side effects.

PharmNovo’s mission is to develop safe and effective treatments for neuropathic pain to accomplish our vision to change the lives of people suffering from this condition.

The company's drug candidate, PN6047, about to enter phase II proof-of-concept studies, has effectively reduced neuropathic pain in preclinical studies. The primary indication is neuropathic pain with allodynia, which is a condition where, for example, light touch triggers severe pain. PharmNovo also sees clinical potential for the drug in other areas, such as migraine, anxiety/depression, and chronic cough.